溴乙那班; 1-(2,4-二氯苯基)-5-(4-溴苯基)-N-(哌啶-1-基)-4-乙基吡唑-3-甲酰胺 | 288104-79-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 溴乙那班; 1-(2,4-二氯苯基)-5-(4-溴苯基)-N-(哌啶-1-基)-4-乙基吡唑-3-甲酰胺
• 中文别名: 溴乙那班;1-(2,4-二氯苯基)-5-(4-溴苯基)-N-(哌啶-1-基)-4-乙基吡唑-3-甲酰胺；1H-咪唑-5-甲腈,2-(2-吡啶基)-；1-(2,4-二氯苯基)-5-(4-溴苯基)-N-(哌啶-1-基)-4-乙基吡唑-3-甲酰胺；溴乙那班
• 英文名称: surinabant
• 英文别名: 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide；5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-piperidin-1-yl-1 H-pyrazole-3-carboxamide；5-(4-bromo-phenyl)-1-(2,4-dichloro-phenyl)-4-ethyl-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide；N-piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide；1-(2,4-dichlorophenyl)-5-(4-bromophenyl)-4-ethyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide；SR 147778；5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-piperidin-1-ylpyrazole-3-carboxamide
• CAS: 288104-79-0
• 化学式: C₂₃H₂₃BrCl₂N₄O
• 分子量: 522.272
• InChiKey: HMXDWDSNPRNUKI-UHFFFAOYSA-N

物化性质

• 密度：
  1.50

计算性质

• 辛醇/水分配系数(LogP)：
  7
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  ethyl 3-(4-Bromobenzoyl)-2-oxopentanoate 、 2,4-二氯苯肼盐酸盐 在 溶剂黄146 作用下， 反应 36.0h， 生成 溴乙那班; 1-(2,4-二氯苯基)-5-(4-溴苯基)-N-(哌啶-1-基)-4-乙基吡唑-3-甲酰胺
  参考文献：
  名称：

  WO2008/102367

  摘要：

  公开号：

文献信息

• [EN] 1,4-DIHYDRONAPHTHYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 1,4-DIHYDRONAPHTYRIDINE
  申请人：PFIZER PROD INC

  公开号：WO2009056934A1

  公开（公告）日：2009-05-07

  A compound of formulae (I) or a prodrug of the compound or a pharmaceutically acceptable salt thereof of the compound or prodrug, wherein the substituents are as defined in the specification, pharmaceutical compositions containing the compounds useful as calcium channel antagonists, and to methods of treating heart disease and pain.

  一种化合物的公式（I）或该化合物的前药或其药用可接受的盐或前药，其中取代基如规范中所定义，含有该化合物的药用组合物可用作钙通道拮抗剂，并用于治疗心脏病和疼痛的方法。
• CB1 Antagonists or inverse agonists as therapeutical agents for the treatment of inflammation involving gene expression
  申请人：LABORATORIOS DEL DR. ESTEVE, S.A.

  公开号：EP1752149A1

  公开（公告）日：2007-02-14

  The present invention relates to substituted pyrazoline compounds, methods for their preparation, medicaments comprising these compounds as well as their use for the preparation of a medicament for the treatment of humans and animal.

  本发明涉及替代吡唑啉化合物，其制备方法，包含这些化合物的药物，以及它们用于制备用于治疗人类和动物的药物的用途。
• Biphenyl-pyrazolecarboxamide compounds
  申请人：Tung Roger

  公开号：US20070066657A1

  公开（公告）日：2007-03-22

  The present invention relates to biphenyl-pyrazole compounds and in particular biphenyl-pyrazolecarboxamides. The invention further provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by antagonism or inverse agonism of the CB 1 receptor, such as obesity, smoking cessation, and normalization of blood lipid composition.

  本发明涉及联苯基吡唑化合物，特别是联苯基吡唑羧酰胺。该发明还提供了包含本发明化合物的组合物，以及利用这些组合物在治疗疾病和状况方面的方法，这些疾病和状况通过CB1受体的拮抗或逆作用有益治疗，如肥胖、戒烟和血脂组成的正常化。
• Diaryl Ether Derivatives and Uses Thereof
  申请人：Ruggeri B. Roger

  公开号：US20080070887A1

  公开（公告）日：2008-03-20

  Compounds of Formula (I) that act as antagonists at the mu, kappa and/or delta opioid receptors and therefore useful in the treatment of diseases, conditions and/or disorders that benefit from such antagonism in animals are described herein. where R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are described herein.

  本文描述了具有化学式（I）的化合物，这些化合物在mu、kappa和/或delta阿片受体上起拮抗作用，因此在动物治疗受益于这种拮抗作用的疾病、状况和/或障碍方面具有用处。其中R1、R2、R3、R4、R5和R6如下描述。
• Derivative of 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(piperidine-1-yl)-1H-pyrazole-3-carboxamide, the preparation and therapeutic use thereof
  申请人：Miscoria Gilles

  公开号：US20060004055A1

  公开（公告）日：2006-01-05

  The invention relates to a derivative of 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide of general formula (I): Preparation process and therapeutic use.

  本发明涉及通式(I)的5-(4-溴苯基)-1-(2,4-二氯苯基)-4-乙基-N-(哌啶-1-基)-1H-吡唑-3-羧酰胺的衍生物：制备方法和治疗用途。